Results 161 to 170 of about 2,290 (211)

Early‐Life Dietary Protein Source Reshapes Gut Microbiota but Fails to Curtail Diet‐Induced Metabolic Syndrome in Young Rats

Obesity, Volume 34, Issue 9, Page 1772-1784, September 2026.
ABSTRACT Objective Dairy consumption plays a protective role in obesity that may be mediated through the gut microbiota. This study examined the role of dairy proteins, casein, whey, and complete dairy (skim milk powder), and a plant‐based alternative, soy, on gut microbiota composition, obesity susceptibility, and insulin sensitivity in early ...
Chunlong Mu, Micaela Hartslief, Jessica Chong, Shrushti Shah, Jennifer Thompson, Raylene A. Reimer, David C. Wright, Jane Shearer   +7 more
wiley   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source

Processing‐Structure‐Function Relationships of Andean Proteins: Quinoa, Amaranth, Cañihua and Tarwi for Sustainable Food Applications

Sustainable Food Proteins, Volume 4, Issue 3, September 2026.
Quinoa, amaranth, tarwi, and cañihua are sustainable protein sources with strong nutritional and techno‐functional potential. Deeper knowledge in processing‐structure–function relationships is crucial for predictive design and large‐scale application in food systems.
Marcela Jarpa‐Parra, Susana Alfaro‐Araya   +1 more
wiley   +1 more source

Objective sleep parameters and diurnal blood pressure in concurrent hypertension and type 2 diabetes

Sleep Research, Volume 3, Issue 3, Page 195-203, September 2026.
Abstract Background Hypertension is a primary cardiovascular complication in type 2 diabetes associated with increased morbidity and mortality. Ambulatory blood pressure monitoring (ABPM) is essential for capturing circadian BP variation, which is closely influenced by sleep. Methods Twenty patients (63.75 ± 4.44 years old, 40% female, duration of T2D:
Yan Zhao, Yuzhe Zha, Yuchan Zheng, Lijun Wei, Baoyi Chen, Zefan Zhang, Xiao Tan   +6 more
wiley   +1 more source

Development and Clinical Utility of Machine Learning Models for Prediction of Same‐Day Discharge in Outpatient Hip and Knee Replacement: A Prognostic Study

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 8, September 2026.
ABSTRACT Background Hip and knee replacement are common procedures with an increasing focus on same‐day surgery. However, capacity constraints limit the number of eligible patients actually being scheduled for same‐day discharge, calling for further selection of those with the highest likelihood of same‐day discharge.
Christoffer C. Jørgensen, Jakob B. Frederiksen, Henrik Kehlet, Martin Lindberg‐Larsen, Kirill Gromov, Claus Varnum, Thomas Jakobsen, Manuel Josef Bieder, Mikkel Rathsach Andersen, Søren Overgaard, Torben B. Hansen, Troels Petersen   +11 more
wiley   +1 more source

Response to Letters to the Editor Regarding ‘Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From a Multi‐Center, Prospective, Observational Study (REVISE Study)’

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Jie‐Eun Lee, Jun Hwa Hong, Min Soo Song, Jong Chul Won   +3 more
wiley   +1 more source

Triangulating the Skeletal Safety of SGLT2 Inhibitors in Diabetes

Journal of Diabetes, Volume 18, Issue 9, September 2026.
Bin Huang, Shujie Yu, Anran Su, Yi Zheng, Yue Teng, Wei Wang   +5 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

Clinical Therapeutics, 2011
Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Julienne Kirk
exaly   +3 more sources

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources